Overview of Sickle Cell Disease (SCD) and the Efficiency of Hydroxyurea for Treating Patients with Sickle Cell

ABDULLAH SAAD ALASMARI,MESHAL ALI S ALASMARI, MOHAMMED SALEH M ALSHAHRANI

Abstract– Sickle-cell disease is a multisystem disease, associated with episodes of intense disease and progressive organ damage, and is among the most typical serious monogenic conditions around the world. We searched Medline, Embase, and Google Scholar for Literature about SCD through 2016, for English, using key words included individual use or a combination of the following: "Hydroxyurea or HU or hydroxycarbamide", "Foetal hemoglobin or HbF or gamma globin", "hemoglobin-induction", "Sickle Cell disease", "SCD treatment" primary publications that described treatment in humans. The majority of people with sickle-cell disease reside in Africa, where little is understood about this disease; nevertheless, we do understand that the condition follows a more extreme medical course in Africa than for the remainder of the world which transmittable illness have a function in triggering this increased seriousness of sickle-cell disease. Hydroxyurea (HU) treatment has actually shown success in numerous settings, both in children and grownups with SCD. hydroxyurea is the only easily offered representative that enhances both scientific and hematologic outcomes. It's understood and possible toxicities must be interpreted in this context, due to the fact that it is suggested for dealing with a disease with incredible morbidity and early death.

Index Terms– Hydroxyurea, HU, hydroxycarbamide, Sickle Cell disease, SCD treatment.

1 INTRODUCTION

SICKLE cell disease is a multisystem disease, associated with episodes of intense disease and progressive organ damage, and is among the most typical serious monogenic conditions around the world [1]. The term sickle-cell (Figure1) disease is utilized to describe all the different genotypes that trigger the particular medical syndrome, whereas sickle-cell anaemia, the most typical type of sickle-cell disease, refers specifically to homozygosity for the βS allele. SCD is brought on by a point anomaly (A > T) in the 6th codon of the β-globin gene on chromosome 11, leading to the replacement of the amino acid glutamic acid to valine [2]. The resulting haemoglobin S (HbS) causes polymerization and rainfall of haemoglobin throughout deoxygenation or dehydration leading to sickling, irregular adhesion of platelets and leukocytes, inflammation, hypoxia, hypercoagulation and haemolysis, in addition to microvascular obstruction and eventually organ damage [3]. There is strong connection in between the frequency of the HbS gene and the historic circulation and occurrences of malaria [4]. It is approximated that more than 300 000 births with SCD happen yearly, almost two-third which happen in Africa [5]. SCD is fairly typical in other continents such as North America and Europe with 2 600 and 1 300 impacted new-borns every year, respectively [6]. It is well accepted that the sickle anomaly exists in Africa on varied hereditary haplotype backgrounds [7]. 5 normal haplotypes have actually been explained throughout the β-globin gene cluster based upon the pattern of particular constraint fragment-length polymorphisms throughout the area. 4 haplotypes are related to HbS in Africa (Benin, Bantu/Central African Republic (CAR), Senegal and Cameroon) and the 5th is believed to have actually developed in India and/or the Arabian Peninsula (Arab/Hindu) [8], [9]. It has actually been recommended that these haplotypes likewise have a result on the seriousness of the disease through their genetically-determined effect on HbF level [10].



Figure 1: Peripheral blood smear of a patient with sickle-cell anaemia (2)

Hydroxyurea was approved by the US Food and Drug Administration (FDA) for the treatment of grownups with sickle cell anemia (HbSS) in 1998 however does not presently have an FDA-approved indicator for children. Hydroxyurea has numerous useful impacts that might add to its effectiveness in SCD. These impacts consist of the induction of fetal hemoglobin (HbF) production [11] with a concomitant boost in overall hemoglobin and reduce in hemolysis with the release of complimentary hemoglobin (a factor to endothelial dysfunction) [12]. Hydroxyurea might likewise be advantageous by decreasing the leukocyte count and the expression of cell-adhesion particles that contribute to vasoocclusion [13].

2 METHODOLOGY

2.1 Data Sources

We searched Medline, Embase, and Google scholar for Literature about SCD through 2016, for English, using key words included individual use or a combination of the following: "Hydroxyurea or HU or hydroxycarbamide", "Foetal hemoglobin or HbF or gamma globin", "hemoglobin-induction", "Sickle Cell disease", "SCD treatment" primary publications that described treatment in humans. We identified additional publications by reviewing reference lists and consulting experts. We included randomized, controlled trials (RCTs), cohort studies with an untreated comparison group, and pre/post studies in which at least 20 participants were treated, because the studies of smaller size were of very low quality and were more likely to be biased. For evidence of toxicity, we also included the Center for the Evaluation of Risks to Human Reproduction review of hydroxyurea, smaller cohort studies, and case reports, we included studies of patients with SCD.

3 RESULTS AND DISCUSSION

3.1 Complication Associated with SCD

Infection as most common complication. Bacterial infections are a significant reason for morbidity and death in patients with sickle-cell disease. The increased vulnerability of afflicted children is most likely to arise from numerous causes, consisting of impaired splenic function, problems in enhance activation, micronutrient shortages, and tissue ischaemia [14]. Numerous organisms, consisting of S pneumoniae, H influenza, and non-typhi Salmonella types, have actually been determined as crucial reasons for infection in industrialized nations, [14] where significant enhancements in diagnosis have actually followed the intro of penicillin prophylaxis and immunisation with conjugate vaccines directed against S pneumoniae and H influenzae type b [15], [16].

Neurological complications associated with SCD. Sickle-cell anaemia is one of the most common reasons for stroke in children. Many cases are connected with vasculopathy aff ecting the distal internal carotid and middle cerebral arteries, although extracranial vasculopathy can likewise exist [17]. The systems for stroke stay unpredictable, contributing elements to this vasculopathy consist of anaemia, leucocytois, hypoxaemia, unusual rheology triggering endothelial damage, practical nitric oxide defi ciency associated with haemolysis, [18] and impaired policy of blood fl ow triggering hyperaemia [19], [20]. The vasculopathy appears to begin in infancy, with a fi rst-stroke occurrence of 1 - 02 per 100 patient-years in between the ages of 2 years and 5 years, and 11% of patients with sickle-cell disease have actually had a stroke by the age of 20 years [21]. Vasculopathy can be identified at an early phase by utilize of transcranial doppler scanning. In the Stroke Prevention in Sickle Cell Anemia (STOP) research study,12 routine blood transfusion to keep HbS listed below 30% decreased the danger of stroke by 90% in patients with increased transcranial doppler speeds [22].

3.2 Hydroxyurea Effectiveness for SCD

A single RCT, the MSH (Multicenter Study of Hydroxyurea for Sickle Cell Anemia), tested the efficacy of hydroxyurea in grownups with sickle cell disease [23]. We determined 6 other studies related to this trial (sub-studies or follow-up research studies) [11], [24], [25], [26], [27], [28]. The MSH was a premium, multicenter trial registering 299 grownups with a mean age of 30.5 years. Nearly all patients (n = 295) had sickle cell anemia; the rest had hemoglobin Sβ0 thalassemia or hemoglobin Sβ+ thalassemia. Patients in the research study got the optimum endured dosage (that restricted by toxicity) or an optimum dosage of 35 mg/kg daily. The primary end point was a decrease in the frequency of uncomfortable crises. The private investigators consisted of a number of secondary end points for which they utilized a more strict requirement for identifying substantial distinctions between groups ($P \leq 0.01$) [29].

Hydroxyurea for secondary stroke avoidance was evaluated in 35 children who terminated persistent transfusions [30]. The rate of reoccurring stroke was 5.7 per 100 patient-years. For contrast, this rate was greater than the 2.2 per 100 person-years reported in a retrospective accomplice research study of children who got continuous transfusions44 however lower than the 70% frequency of frequent stroke seen in the very first year after terminating transfusion without alternative treatments [31]. Another research study reported steady MRI of the brain throughout hydroxyurea treatment in 24 of 25 children [33]. In the Belgian Registry, throughout 426 patient-years of hydroxyurea treatment, the rate of stroke or short-term ischemic attacks was 1.3 per 100 patient-years, however no contrast rate was supplied [34]. 2 research studies [35], [36] reported transcranial Doppler (TCD) speeds, due to the fact that raised speeds are related to an increased threat of stroke. Kratovil et al [35] explained a reduction in the mean optimum speed with hydroxyurea treatment from 125 to 111 cm/second. A neglected control group had a boost in speed over the very same period of 4.7 cm/second. Zimmerman et al [36] prospectively studied 36 children who had repeat TCD after a mean of 10 months on hydroxyurea. In general, speeds reduced substantially, and in 14 of 15 children with conditional standard TCD speeds (170-199 cm/second), the worths decreased; in 5 of 6 with irregular speeds (200 cm/second), whose households decreased transfusions, the speeds reduced to 200 cm/second.

4 CONCLUSION

The majority of people with sickle-cell disease reside in Africa, where little is understood about this disease; nevertheless, we do understand that the condition follows a more extreme medical course in Africa than for the remainder of the world which transmittable illness have a function in triggering this increased seriousness of sickle-cell disease. Hydroxyurea (HU) treatment has actually shown success in numerous settings, both in children and grownups with SCD. hydroxyurea is the only easily offered representative that enhances both scientific and hematologic

outcomes. It's understood and possible toxicities must be interpreted in this context, due to the fact that it is suggested for dealing with a disease with incredible morbidity and early death.

REFERENCES

[1] D. Weatherall, K. Hofman, G. Rodgers, J. Ruffi, S. Hrynkow, "A Case for Developing North-South Partnerships for Research in Sickle Cell Disease," *Blood,* vol. 105, no. 3, pp. 921-218, Feb. 2005.

[2] JB. Herrick, "Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in a Case of Severe Anemia," *Arch Intern Med,* vol. 312, no. 10, pp. 517-21, Sep. 2014.

[3] P. Bartolucci and F. Galacteros, "Clinical Management of Adult Sickle-Cell Disease." *Curr Opin Hematol,* vol. 19, no. 3, pp. 149-155, May 2012.

[4] T. Williams, T. Mwangi, S. Wambua, N. Alexander, M. Kortok, R. Snow, K. Marsh, "Sickle Cell Trait and the Risk of Plasmodium Falciparum Malaria and Other Childhood Diseases," *J. Infect Dis.*, vol. 192, no. 1, pp. 178-186, Jul. 2005.

[5] F. Piel, A. Patil, R. Howes, O. Nyangiri, P. Gething, M. Dewi, W. Temperly, T. Williams, D. Weatherall, and S. Hay, "Global Epidemiology of Sickle Haemoglobin in Neonates: a Contemporary Geostatistical Model-Based Map and Population Estimates," *The Lancet*, vol. 381, no. 9861, pp. 142-151, Jan. 2013.

[6] B. Modell and M. Darlison, "Global Epidemiology of Haemoglobin Disorders and Derived Service Indicators," *Bull World Health Organ*, vol. 86, no. 6, pp.480-487, Jun. 2008.

[7] D. Labie, J. Pagnier, C. Lapoumeroulie, F. Rouabhi, O. DundaBelkhodja, P. Chardin, C. Beldjord, H. Wadjcman, M. Fabry, and R. Nagel, "Common Haplotype Dependency of High G Gamma-Globin Gene Expression and High Hb F Levels in Beta-Thalassemia and Sickle Cell Anemia Patients," *Proc Natl Acad Sci U S A,* vol. 82, no. 7, 1985, pp. 2111-2114, Apr. 1985.

[8] J. Elion, P. Berg, C. Lapoumeroulie, G. Trabuchet, M. Mittelman, R. Schechter, and D. Labie, "DNA Sequence Variation in a Negative Control Region 5' to the Beta-Globin Gene Correlates with the Phenotypic Expression of the Beta SMutation," *Blood*, vol. 79, no. 3, pp. 787-792, Feb. 1992.

[9] J. Pagnier, J. Mears, O. Dunda-Belkhodja, K. Schaefer-Rego, C. Beldjord, R. Nagel, and D. Labie, "Evidence for the Multicentric Origin of the Sickle Cell Hemoglobin Gene in Africa," *Proc Natl Acad Sci U S A*, vol. 81, no. 6, pp. 1771-1773, Mar. 1984.

[10] M. Steinberg, "Genetic Etiologies for Phenotypic Diversity in Sickle Cell Anemia," *TheScientific World Journal,* vol. 9, pp. 46-67, Jan. 2009.

[11] S. Charache, F. Barton, R.D. Moore, M.L. Terrin, M.H. Steinberg, G. Dover, S. Ballas, R. McMahon, O. Castro, E. Orringer, "Hydroxyurea and Sickle Cell Anemia. Clinical Utility of a Myelosuppressive "Switching" Agent," *Medicine,* vol. 75, no. 6 pp. 300-326, Nov. 1996.

[12] G. Kato, M. Gladwin, and M. Steinberg, "Deconstructing Sickle Cell Disease: Reappraisal of the Role of Hemolysis in the Development of Clinical Subphenotypes," *Blood Rev.*, vol. 21, no. 1, pp. 37-47, Jan. 2007.

[13] M. Benkerrou, C. Delarche, L. Brahimi, M. Fay, E. Vilmer, J. Elion, M. Gougerot-Pocidalo, and C. Elbim, "Hydroxyurea Corrects the Dysregulated L-selectin Expression and Increased H2O2 Production of Polymorphonuclear Neutrophils from Patients with Sickle Cell Anemia," *Blood*, vol. 99, no. 7, pp. 2297–2303, Apr. 2002.

[14] G.R. Serjeant, B.E. Serjeant, Sickle cell disease. Oxford, UK. Oxford University Press, pp. _____, 2001.

[15] A. John, A. Ramlal, H. Jackson, G. Maude, A. Sharma, and G. Serjeant, "Prevention of Pneumococcal Infection in Children with Homozygous Sickle Cell Disease," *Br Med J,* vol. 288, no. 6430, pp. 1567-1570, May 1984.

[16] M. Gaston, J. Verter, G. Woods, C. Pegelow, J. Kelleher, G. Presbury, H. Zarkowsky, E. Vichinsky, R. Iyer, J. Lobel, and S. Diamond, "Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia," *N Engl J Med,* vol. 314, no. 25, pp. 1593–99, Jun. 1986.

[17] C. Deane, D. Goss, J. Bartram, K. Pohl, S. Height, N. Sibtain, J. Jarosz, S. Thein, and D. Rees, "Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Anaemia," *Haematologica*, vol. 95, no. 8, pp. 1287–92, Aug. 2010.

[18] S. O'Driscoll, S. Height, M. Dick, D. Rees, "Serum Lactate Dehydrogenase as a Biomarker in Children with Sickle Cell Disease," *Br J Haematol*, vol. 140, no. 2, pp. 206-209, Jan. 2008.

[19] J.A. Switzer, D.C. Hess, F.T. Nichols and R.J. Adams, "Pathophysiology and Treatment of Stroke in Sickle-Cell Disease: Present and Future," *Lancet Neurol,* vol. 5, no. 6, pp. 501-512, Jun 2006.

[20] I. Prohovnik, A. Hurlet-Jensen, R. Adams, D. De Vivo and S.G. Pavlakis, "Hemodynamic Etiology of Elevated Flow Velocity and Stroke in Sickle-Cell Disease," *J Cereb Blood Flow Metab,* vol. 29, no. 4, pp. 803-810, Apr. 2009.

[21] K. Ohene-Frempong, S.J. Weiner, L.A. Sleeper, S.T. Miller, S. Embury, J.W. Moohr, D.L. Wethers, C.H. Pegelow and F.M. Gill, "Cerebrovascular Accidents in Sickle Cell Disease: Rates and Risk Factors," *Blood* vol. 91, no. 1, pp. 288-294, Jan. 1998.

[22] R.J. Adams, V.C. McKie, L. Hsu, B. Files, E. Vichinsky, C. Pegelow, M. Abboud, D. Gallagher, A. Kutlar, F.T. Nicholas, D.R. Bonds and D. Brambilla, "Prevention of aFirst Stroke By Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography," *N Engl J Med* vol. 339, no. 1, pp. 5-11, Jul. 1998.

[23] S. Charache, M.L. Terrin, R.D. Moore, G.J. Dover, F.B. Barton, S.V. Eckert, R.P. McMahon and D.R. Bonds, "Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia," *N Engl J Me,* vol. 332, no. 20, pp. 1317-1322. May 1995.

[24] M.H. Steinberg, Z.H. Lu, F.B. Barton, M.L. Terrin, S. Charache and G.J. Dover, "Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to Hydroxyurea. Multicenter Study of Hydroxyurea," *Blood,* vol. 89, no. 3, pp. 1078-1088, Feb 1997.

[25] A.C. Hackney, W. Hezier, T.P. Gulledge, S. Jones, D. Strayhorn, M. Busby, E. Hoffman and E.P. Orringer, "Effects of Hydroxyurea Administration on the Body Weight, Body Composition and Exercise Performance of Patients with Sickle-Cell Anaemia," *Clin Sci (Lond)*, vol. 92, no. 5, pp. 481-486, May 1997.

[26] S.K. Ballas, F.B Barton, M.A. Waclawiw, P. Swerdlow, J.R. Eckman, C.H. Pegelow, M. Koshy, B.A. Barton and D.R. Bonds, "Hydroxyurea and Sickle Cell Anemia: Effect on Quality of Life," *Health Qual Life* Outcomes vol. 4, no 59, Aug. 2006.

[27] R.D. Moore, S. Charache, M.L. Terrin, F.B. Barton and S.K. Ballas, "Cost-Effectiveness of Hydroxyurea in Sickle Cell Anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia," *Am J Hematol* vol. 64, no. 1, pp. 26-31, May 2000.

[28] M.H. Steinberg, F. Barton, O. Castro, C.H. Pegelow, S.K Ballas, A. Kutlar, E. Orringer, R. Bellvue, N. Olivieri, J. Eckman, M. Varma, G. Ramirez, B. Adler, W. Smith, T. Carlos, K. Ataga, L. DeCastro, C. Bigelow, Y. Saunthararajah, M. Telfer, E. Vichinsky, S. Clasterm S. Shurin, K. Bridges,

M. Waclawiw, D. Bonds and M. Terrin, "Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks And Benefits Up to 9 Years of Treatment," *JAMA*, vol. 289, no. 3, pp. 1645-1651, Apr. 2003.

[29] S. Charache, M.L Terrin, R.D. Moore, G.J. Dover, R.P. McMahon, F.B Barton, M. Waclawiw and S.V. Eckert, "Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Investigators of the Multicenter Study of Hydroxyurea," *Control Clin Trials* vol. 16, no. 6, Dec. 1995.

[30] R.E. Ware, S.A. Zimmerman, P.B. Sylvestre, N.A. Mortier, J.S. Davis, W.R. Treem and W.H. Schultz, "Prevention of Secondary Stroke and Resolution of Transfusional Iron Overload in Children with Sickle Cell Anemia using Hydroxyurea and Phlebotomy," *J. Pediatr* Vol. 145, no. 3, pp. 346-352, Sep. 2004.

[31] J. Wilimas, J.R. Goff, H.R. Anderson Jr., J.W. Langston and E. Thompson, "Efficacy of Transfusion Therapy for One to Two Years in Patients with Sickle Cell Disease and Cerebrovascular Accidents," *J. Pediatr*, vol. 96, no.2, pp. 205-208, Feb. 1980.

[32] J. S. Hankins, K.J. Helton, M.B. McCarville, C.S. Li, W.C. Wang and R.E. Ware, "Preservation of Spleen and Brain Function in Children with Sickle Cell Anemia Treated with Hydroxyurea," *Pediatr Blood Cancer*. Vol. 50 no. 2, pp. 293-297, Feb. 2008.

[33] M. de Montalembert, M. Belloy, F. Bernaudin, F. Gouraud, R. Capdeville, R. Mardini, N. Philippe, J.P. Jais, J. Bardakdian, R. Ducrocq, M. Maier-Redelsperger, J. Elion, D. Labie andR. Girot, "Three-Year Follow-Up of Hydroxyurea Treatment in Severely Ill Children with Sickle Cell Disease. The French Study Group on Sickle Cell Disease," *J Pediatr Hematol Oncol,* vol. 19, no. 4, pp. 313-318, Jul-Aug 1997.

[34] B. Gulbis, D. Haberman, D. Dufour, C. Christophe, C. Vermylen, F. Kagambega, F. Corazza, C. Devalck, M.F. Dresse, K. Hunninck, A. Klein, P.Q. Le, M. Loop, P. Maes, P. Philippet, E. Sariban, C. Van Geet and A. Fester, "Hydroxyurea for Sickle Cell Disease in Children and for Prevention of Cerebrovascular Events: The Belgian Experience," *Blood*, vol. 105, no. 7, pp. 2685-2690, Apr. 2005.

[35] T. Kratovil, D. Bulas, M.C. Driscoll, B. Speller-Brown, R. McCarter and C.P. Minniti, "Hydroxyurea Therapy Lowers TCD Velocities in Children with Sickle Cell Disease," *Pediatr. Blood Cancer, vol. 47, no. 7, pp. 894-900, Dec.* 2006.

[36] S.A. Zimmerman, W.H Schultz, S. Burgett, N.A. Mortier and R.E. Ware. "Hydroxyurea Therapy Lowers Transcranial Doppler Flow Velocities in Children with Sickle Cell Anemia," *Blood,* vol. 110, no. 3, pp. 1043-1047, Aug. 2007.